"In addition, we expect to begin the pivotal THRIVE-3 study of intravenous (IV) Choline Chloride in the first half of 2025.

Choline Chloride, the Company’s investigational IV phospholipid substrate replacement therapy, as a source of choli TARA-002 demonstrated compelling efficacy and was generally well-tolerated ...

Reported positive six-month data from ADVANCED-2 trial of TARA-002 in patients with NMIBC Completed approximately $100 million public offering, extending runway into 2027 Initial data from 12-month ev ...

In December 2024, the Company reported positive interim results from its ongoing Phase 2 open-label ADVANCED-2 trial in in ...

After hours: January 15 at 5:18:40 PM EST Loading Chart for BCPC ...

Its candidate UNR844 (lipoic acid/choline ester chloride) – acquired with Encore Vision in 2017 – works by restoring the elasticity of the lens. AbbVie agrees a $200 million-plus takeover deal ...

Its candidate UNR844 (lipoic acid/choline ester chloride) – acquired with Encore Vision in 2017 – works by restoring the elasticity of the lens.

Nippon India Nifty Smallcap 250 Index Fund (G) 2.02 11,278 0.10 Nippon India Nifty Smallcap 250 Index Fund (IDCW) 2.02 11,278 0.10 Nippon India Nifty Smallcap 250 ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...